Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 USD | +1.33% | -7.69% | -2.15% |
Jun. 07 | Top Premarket Gainers | MT |
Jun. 05 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.15% | 33.12M | |
+48.39% | 779B | |
+40.44% | 631B | |
-6.13% | 354B | |
+20.61% | 333B | |
+10.00% | 301B | |
+16.74% | 249B | |
-1.76% | 216B | |
+11.03% | 214B | |
+5.80% | 163B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Insider Trends: Insider Sales Add to 90-Day Trend at VYNE Therapeutics